Skip to main content
. Author manuscript; available in PMC: 2006 Oct 5.
Published in final edited form as: Eur J Neurosci. 2004 Nov;20(10):2491–2498. doi: 10.1111/j.1460-9568.2004.03717.x

Fig. 1.

Fig. 1

Endogenous corticosterone decreases post-mitotic survival. (A) Design of Experiment 1. (B) Mean ± SE of surviving BrdU-labelled cells over time for the three treatment groups: sham-operated (▪), adrenalectomized (ADX) (▴) and ADX with basal corticosterone replacement (ADX Low corticosterone) (▾) (§P < 0.023; †P< 0.0001). Additional corticosterone reduces post-mitotic survival. (C) Design of Experiment 2. (D) Mean ± SE of surviving BrdU-labelled cells over time for animals receiving daily injection of oil (▪) or high corticosterone (40 mg/kg) (▴) (§P < 0.007; †P < 0.04; ‡P < 0.029). (E–G) Twenty-eight-day-old BrdU-labelled cells in dentate gyrus in sham, ADX and ADX Low corticosterone animals, respectively. (H, I) Twenty-eight-day-old BrdU-labelled cells in oil or high corticosterone-treated animals, respectively. (J) Morphology of BrdU-labelled cells at high magnification.